Nilutamide is an antineoplastic hormone used to treat prostate cancer. Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors).
- Mechanism
- Curator reviewed
Nilutamide competes with androgen for the binding of androgen receptors, consequently blocking the action of androgens of adrenal and testicular origin that stimulate the growth of normal and malignant prostatic tissue. This blockade of androgen receptors may result in growth arrest or transient tumor regression through inhibition of androgen-dependent DNA and protein synthesis.
- Primary indication
- For use in combination with surgical castration for the treatment of metastatic prostate cancer involving distant lymph nodes, bone, or visceral organs (Stage D2).Curator reviewed · 1 structured indication
- Formula / weight
- C12H10F3N3O4 · 317.2207 g/mol (avg)
- First approval
- Canada, 2000 · United States, 1996
- Code names
- RU-23908
- Brand names
Resolves to
XWXYUMMDTVBTOU-UHFFFAOYSA-NSMILESCC1(C)NC(=O)N(C1=O)C1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)FWhat you can answer from here — as of September 12, 2026
Which drugs share a target with Nilutamide, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account